ID   EPHA8_HUMAN             Reviewed;        1005 AA.
AC   P29322; Q6IN80; Q8IUX6; Q9NUA9; Q9P269;
DT   01-DEC-1992, integrated into UniProtKB/Swiss-Prot.
DT   18-OCT-2001, sequence version 2.
DT   10-MAY-2017, entry version 187.
DE   RecName: Full=Ephrin type-A receptor 8;
DE            EC=2.7.10.1;
DE   AltName: Full=EPH- and ELK-related kinase;
DE   AltName: Full=EPH-like kinase 3;
DE            Short=EK3;
DE            Short=hEK3;
DE   AltName: Full=Tyrosine-protein kinase receptor EEK;
DE   Flags: Precursor;
GN   Name=EPHA8; Synonyms=EEK, HEK3, KIAA1459;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Brain, and Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 153-1005 (ISOFORM 1), AND
RP   VARIANT GLN-612.
RC   TISSUE=Brain;
RX   PubMed=10819331; DOI=10.1093/dnares/7.2.143;
RA   Nagase T., Kikuno R., Ishikawa K., Hirosawa M., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XVII.
RT   The complete sequences of 100 new cDNA clones from brain which code
RT   for large proteins in vitro.";
RL   DNA Res. 7:143-150(2000).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 706-726.
RX   PubMed=1648701;
RA   Chan J., Watt V.M.;
RT   "eek and erk, new members of the eph subclass of receptor protein-
RT   tyrosine kinases.";
RL   Oncogene 6:1057-1061(1991).
RN   [5]
RP   NOMENCLATURE.
RX   PubMed=9267020;
RG   Eph nomenclature committee;
RT   "Unified nomenclature for Eph family receptors and their ligands, the
RT   ephrins.";
RL   Cell 90:403-404(1997).
RN   [6]
RP   INTERACTION WITH FYN.
RX   PubMed=10498895; DOI=10.1038/sj.onc.1202917;
RA   Choi S., Park S.;
RT   "Phosphorylation at Tyr-838 in the kinase domain of EphA8 modulates
RT   Fyn binding to the Tyr-615 site by enhancing tyrosine kinase
RT   activity.";
RL   Oncogene 18:5413-5422(1999).
RN   [7]
RP   INTERACTION WITH PIK3CG.
RX   PubMed=11416136; DOI=10.1128/MCB.21.14.4579-4597.2001;
RA   Gu C., Park S.;
RT   "The EphA8 receptor regulates integrin activity through p110gamma
RT   phosphatidylinositol-3 kinase in a tyrosine kinase activity-
RT   independent manner.";
RL   Mol. Cell. Biol. 21:4579-4597(2001).
RN   [8]
RP   INTERACTION WITH ANKS1B.
RX   PubMed=17875921; DOI=10.1128/MCB.00794-07;
RA   Shin J., Gu C., Park E., Park S.;
RT   "Identification of phosphotyrosine binding domain-containing proteins
RT   as novel downstream targets of the EphA8 signaling function.";
RL   Mol. Cell. Biol. 27:8113-8126(2007).
RN   [9]
RP   INTERACTION WITH TIAM1.
RX   PubMed=20496116; DOI=10.1007/s10059-010-0075-2;
RA   Yoo S., Shin J., Park S.;
RT   "EphA8-ephrinA5 signaling and clathrin-mediated endocytosis is
RT   regulated by Tiam-1, a Rac-specific guanine nucleotide exchange
RT   factor.";
RL   Mol. Cells 29:603-609(2010).
RN   [10]
RP   STRUCTURE BY NMR OF 437-534 AND 932-1000.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the second FN3 domain and of sterile alpha
RT   motif (SAM) domain of EPH receptor A8 protein.";
RL   Submitted (NOV-2005) to the PDB data bank.
RN   [11]
RP   VARIANTS [LARGE SCALE ANALYSIS] SER-45; LEU-60; LYS-123; CYS-179;
RP   LEU-198 AND LEU-860.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Receptor tyrosine kinase which binds promiscuously GPI-
CC       anchored ephrin-A family ligands residing on adjacent cells,
CC       leading to contact-dependent bidirectional signaling into
CC       neighboring cells. The signaling pathway downstream of the
CC       receptor is referred to as forward signaling while the signaling
CC       pathway downstream of the ephrin ligand is referred to as reverse
CC       signaling. The GPI-anchored ephrin-A EFNA2, EFNA3, and EFNA5 are
CC       able to activate EPHA8 through phosphorylation. With EFNA5 may
CC       regulate integrin-mediated cell adhesion and migration on
CC       fibronectin substrate but also neurite outgrowth. During
CC       development of the nervous system plays also a role in axon
CC       guidance. Downstream effectors of the EPHA8 signaling pathway
CC       include FYN which promotes cell adhesion upon activation by EPHA8
CC       and the MAP kinases in the stimulation of neurite outgrowth (By
CC       similarity). {ECO:0000250}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028}.
CC   -!- SUBUNIT: Heterotetramer upon binding of the ligand. The
CC       heterotetramer is composed of an ephrin dimer and a receptor
CC       dimer. Oligomerization is probably required to induce biological
CC       responses. May also form heterodimers with other ephrin receptors
CC       (By similarity). Interacts with FYN; possible downstream effector
CC       of EPHA8 in regulation of cell adhesion. Interacts with PIK3CG;
CC       regulates integrin-mediated cell adhesion to substrate. Interacts
CC       with TIAM1; regulates clathrin-mediated endocytosis of EPHA8.
CC       Interacts with ANKS1A and ANKS1B; EPHA8 kinase activity-
CC       independent but stimulated by EPHA8 ubiquitination. {ECO:0000250,
CC       ECO:0000269|PubMed:10498895, ECO:0000269|PubMed:11416136,
CC       ECO:0000269|PubMed:17875921, ECO:0000269|PubMed:20496116}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane
CC       {ECO:0000250|UniProtKB:O09127}; Single-pass type I membrane
CC       protein {ECO:0000255}. Cell projection
CC       {ECO:0000250|UniProtKB:O09127}. Early endosome membrane
CC       {ECO:0000250|UniProtKB:O09127}. Note=Undergoes clathrin-mediated
CC       endocytosis upon EFNA5-binding and is targeted to early endosomes.
CC       {ECO:0000250|UniProtKB:O09127}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P29322-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P29322-2; Sequence=VSP_041946, VSP_041947;
CC         Note=No experimental confirmation available.;
CC   -!- PTM: Phosphorylated. Phosphorylation is stimulated upon binding of
CC       its ligands including EFNA2, EFNA3 and EFNA5. Autophosphorylation
CC       on Tyr-616 is critical for association with FYN.
CC       Autophosphorylation on Tyr-839 modulates tyrosine kinase activity
CC       (By similarity). {ECO:0000250}.
CC   -!- PTM: Ubiquitinated. Ubiquitination by CBL regulates the receptor
CC       stability and activity through proteasomal degradation. ANKS1A
CC       prevents ubiquitination and degradation (By similarity).
CC       {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Ephrin receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAA41980.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AL035703; CAB81612.1; -; Genomic_DNA.
DR   EMBL; AL035703; CAI22039.1; -; Genomic_DNA.
DR   EMBL; BC038796; AAH38796.1; -; mRNA.
DR   EMBL; BC072417; AAH72417.2; -; mRNA.
DR   EMBL; AB040892; BAA95983.1; -; mRNA.
DR   EMBL; X59291; CAA41980.1; ALT_INIT; Genomic_DNA.
DR   CCDS; CCDS225.1; -. [P29322-1]
DR   CCDS; CCDS30626.1; -. [P29322-2]
DR   PIR; S23361; S23361.
DR   RefSeq; NP_001006944.1; NM_001006943.2. [P29322-2]
DR   RefSeq; NP_065387.1; NM_020526.4. [P29322-1]
DR   UniGene; Hs.283613; -.
DR   PDB; 1UCV; NMR; -; A=933-1000.
DR   PDB; 1X5L; NMR; -; A=437-534.
DR   PDB; 3KUL; X-ray; 2.15 A; A/B=602-909.
DR   PDBsum; 1UCV; -.
DR   PDBsum; 1X5L; -.
DR   PDBsum; 3KUL; -.
DR   ProteinModelPortal; P29322; -.
DR   SMR; P29322; -.
DR   BioGrid; 108360; 12.
DR   IntAct; P29322; 7.
DR   STRING; 9606.ENSP00000166244; -.
DR   BindingDB; P29322; -.
DR   ChEMBL; CHEMBL4134; -.
DR   GuidetoPHARMACOLOGY; 1828; -.
DR   iPTMnet; P29322; -.
DR   PhosphoSitePlus; P29322; -.
DR   BioMuta; EPHA8; -.
DR   DMDM; 19857975; -.
DR   EPD; P29322; -.
DR   MaxQB; P29322; -.
DR   PaxDb; P29322; -.
DR   PeptideAtlas; P29322; -.
DR   PRIDE; P29322; -.
DR   DNASU; 2046; -.
DR   Ensembl; ENST00000166244; ENSP00000166244; ENSG00000070886. [P29322-1]
DR   Ensembl; ENST00000374644; ENSP00000363775; ENSG00000070886. [P29322-2]
DR   GeneID; 2046; -.
DR   KEGG; hsa:2046; -.
DR   UCSC; uc001bfw.4; human. [P29322-1]
DR   CTD; 2046; -.
DR   DisGeNET; 2046; -.
DR   GeneCards; EPHA8; -.
DR   HGNC; HGNC:3391; EPHA8.
DR   HPA; CAB009660; -.
DR   HPA; HPA031433; -.
DR   MIM; 176945; gene.
DR   neXtProt; NX_P29322; -.
DR   OpenTargets; ENSG00000070886; -.
DR   PharmGKB; PA27823; -.
DR   eggNOG; KOG0196; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000118975; -.
DR   HOGENOM; HOG000233856; -.
DR   HOVERGEN; HBG062180; -.
DR   InParanoid; P29322; -.
DR   KO; K05109; -.
DR   OMA; EPHNYEE; -.
DR   OrthoDB; EOG091G00W0; -.
DR   PhylomeDB; P29322; -.
DR   TreeFam; TF315608; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   Reactome; R-HSA-2682334; EPH-Ephrin signaling.
DR   Reactome; R-HSA-3928663; EPHA-mediated growth cone collapse.
DR   Reactome; R-HSA-3928665; EPH-ephrin mediated repulsion of cells.
DR   SignaLink; P29322; -.
DR   SIGNOR; P29322; -.
DR   EvolutionaryTrace; P29322; -.
DR   GeneWiki; EPHA8; -.
DR   GenomeRNAi; 2046; -.
DR   PRO; PR:P29322; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000070886; -.
DR   CleanEx; HS_EPHA8; -.
DR   Genevisible; P29322; HS.
DR   GO; GO:0031901; C:early endosome membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005887; C:integral component of plasma membrane; ISS:UniProtKB.
DR   GO; GO:0043005; C:neuron projection; ISS:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005004; F:GPI-linked ephrin receptor activity; ISS:UniProtKB.
DR   GO; GO:0007411; P:axon guidance; ISS:UniProtKB.
DR   GO; GO:0007155; P:cell adhesion; IEA:UniProtKB-KW.
DR   GO; GO:0071372; P:cellular response to follicle-stimulating hormone stimulus; IEA:Ensembl.
DR   GO; GO:0048013; P:ephrin receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0031175; P:neuron projection development; ISS:UniProtKB.
DR   GO; GO:0016322; P:neuron remodeling; ISS:UniProtKB.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; ISS:UniProtKB.
DR   GO; GO:0043552; P:positive regulation of phosphatidylinositol 3-kinase activity; ISS:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; ISS:UniProtKB.
DR   GO; GO:0030155; P:regulation of cell adhesion; ISS:UniProtKB.
DR   GO; GO:0033628; P:regulation of cell adhesion mediated by integrin; ISS:UniProtKB.
DR   GO; GO:0006929; P:substrate-dependent cell migration; ISS:UniProtKB.
DR   CDD; cd00063; FN3; 2.
DR   Gene3D; 2.60.120.260; -; 1.
DR   Gene3D; 2.60.40.10; -; 2.
DR   InterPro; IPR027936; Eph_TM.
DR   InterPro; IPR001090; Ephrin_rcpt_lig-bd_dom.
DR   InterPro; IPR020691; EphrinA_rcpt8.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR008979; Galactose-bd-like.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001660; SAM.
DR   InterPro; IPR013761; SAM/pointed.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR011641; Tyr-kin_ephrin_A/B_rcpt-like.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR016257; Tyr_kinase_ephrin_rcpt.
DR   InterPro; IPR001426; Tyr_kinase_rcpt_V_CS.
DR   PANTHER; PTHR24416:SF476; PTHR24416:SF476; 1.
DR   Pfam; PF14575; EphA2_TM; 1.
DR   Pfam; PF01404; Ephrin_lbd; 1.
DR   Pfam; PF00041; fn3; 2.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF00536; SAM_1; 1.
DR   PIRSF; PIRSF000666; TyrPK_ephrin_receptor; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00615; EPH_lbd; 1.
DR   SMART; SM01411; Ephrin_rec_like; 1.
DR   SMART; SM00060; FN3; 2.
DR   SMART; SM00454; SAM; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF47769; SSF47769; 1.
DR   SUPFAM; SSF49265; SSF49265; 1.
DR   SUPFAM; SSF49785; SSF49785; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS01186; EGF_2; 1.
DR   PROSITE; PS51550; EPH_LBD; 1.
DR   PROSITE; PS50853; FN3; 2.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00790; RECEPTOR_TYR_KIN_V_1; 1.
DR   PROSITE; PS00791; RECEPTOR_TYR_KIN_V_2; 1.
DR   PROSITE; PS50105; SAM_DOMAIN; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell adhesion;
KW   Cell membrane; Cell projection; Complete proteome;
KW   Developmental protein; Endosome; Glycoprotein; Kinase; Membrane;
KW   Neurogenesis; Nucleotide-binding; Phosphoprotein; Polymorphism;
KW   Receptor; Reference proteome; Repeat; Signal; Transferase;
KW   Transmembrane; Transmembrane helix; Tyrosine-protein kinase;
KW   Ubl conjugation.
FT   SIGNAL        1     27       {ECO:0000255}.
FT   CHAIN        28   1005       Ephrin type-A receptor 8.
FT                                /FTId=PRO_0000016822.
FT   TOPO_DOM     28    542       Extracellular. {ECO:0000255}.
FT   TRANSMEM    543    563       Helical. {ECO:0000255}.
FT   TOPO_DOM    564   1005       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       31    209       Eph LBD. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00883}.
FT   DOMAIN      328    438       Fibronectin type-III 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      439    534       Fibronectin type-III 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      635    896       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   DOMAIN      930    994       SAM. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00184}.
FT   NP_BIND     641    649       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION      564    570       Mediates interaction with ANKS1A and
FT                                ANKS1B. {ECO:0000250}.
FT   REGION      589    644       Mediates interaction with PIK3CG and
FT                                required for endocytosis. {ECO:0000250}.
FT   MOTIF      1003   1005       PDZ-binding. {ECO:0000255}.
FT   COMPBIAS    191    325       Cys-rich.
FT   ACT_SITE    760    760       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     667    667       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES     616    616       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     839    839       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   CARBOHYD    340    340       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    407    407       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    432    432       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   VAR_SEQ     439    495       APSQVVVIRQERAGQTSVSLLWQEPEQPNGIILEYEIKYYE
FT                                KDKEMQSYSTLKAVTT -> GRRRNSVPQRPGPPASPASDP
FT                                SRDQSSAGDVLWAFRQVPLWPCAPHQDPELEALHCL (in
FT                                isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_041946.
FT   VAR_SEQ     496   1005       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_041947.
FT   VARIANT      45     45       G -> S (in dbSNP:rs45498698).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042153.
FT   VARIANT      60     60       V -> L (in dbSNP:rs56402644).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042154.
FT   VARIANT     123    123       N -> K (in a breast infiltrating ductal
FT                                carcinoma sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042155.
FT   VARIANT     179    179       R -> C (in a gastric adenocarcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042156.
FT   VARIANT     198    198       R -> L (in a lung adenocarcinoma sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042157.
FT   VARIANT     321    321       P -> L (in dbSNP:rs56656925).
FT                                /FTId=VAR_061292.
FT   VARIANT     444    444       V -> M (in dbSNP:rs2295021).
FT                                /FTId=VAR_022107.
FT   VARIANT     612    612       E -> Q (in dbSNP:rs999765).
FT                                {ECO:0000269|PubMed:10819331}.
FT                                /FTId=VAR_024514.
FT   VARIANT     860    860       P -> L (in a metastatic melanoma sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042158.
FT   CONFLICT    237    237       S -> L (in Ref. 3; BAA95983).
FT                                {ECO:0000305}.
FT   STRAND      456    460       {ECO:0000244|PDB:1X5L}.
FT   STRAND      472    482       {ECO:0000244|PDB:1X5L}.
FT   STRAND      488    499       {ECO:0000244|PDB:1X5L}.
FT   STRAND      507    510       {ECO:0000244|PDB:1X5L}.
FT   STRAND      512    516       {ECO:0000244|PDB:1X5L}.
FT   STRAND      527    530       {ECO:0000244|PDB:1X5L}.
FT   HELIX       632    634       {ECO:0000244|PDB:3KUL}.
FT   STRAND      635    643       {ECO:0000244|PDB:3KUL}.
FT   TURN        644    646       {ECO:0000244|PDB:3KUL}.
FT   STRAND      647    654       {ECO:0000244|PDB:3KUL}.
FT   STRAND      662    669       {ECO:0000244|PDB:3KUL}.
FT   HELIX       675    688       {ECO:0000244|PDB:3KUL}.
FT   STRAND      699    703       {ECO:0000244|PDB:3KUL}.
FT   HELIX       705    707       {ECO:0000244|PDB:3KUL}.
FT   STRAND      710    714       {ECO:0000244|PDB:3KUL}.
FT   HELIX       721    726       {ECO:0000244|PDB:3KUL}.
FT   TURN        727    730       {ECO:0000244|PDB:3KUL}.
FT   HELIX       734    753       {ECO:0000244|PDB:3KUL}.
FT   HELIX       763    765       {ECO:0000244|PDB:3KUL}.
FT   STRAND      766    768       {ECO:0000244|PDB:3KUL}.
FT   STRAND      774    776       {ECO:0000244|PDB:3KUL}.
FT   HELIX       802    804       {ECO:0000244|PDB:3KUL}.
FT   HELIX       807    812       {ECO:0000244|PDB:3KUL}.
FT   HELIX       817    832       {ECO:0000244|PDB:3KUL}.
FT   TURN        833    835       {ECO:0000244|PDB:3KUL}.
FT   TURN        838    841       {ECO:0000244|PDB:3KUL}.
FT   HELIX       844    852       {ECO:0000244|PDB:3KUL}.
FT   HELIX       865    874       {ECO:0000244|PDB:3KUL}.
FT   HELIX       879    881       {ECO:0000244|PDB:3KUL}.
FT   HELIX       885    897       {ECO:0000244|PDB:3KUL}.
FT   HELIX       935    941       {ECO:0000244|PDB:1UCV}.
FT   HELIX       945    947       {ECO:0000244|PDB:1UCV}.
FT   HELIX       948    953       {ECO:0000244|PDB:1UCV}.
FT   HELIX       959    962       {ECO:0000244|PDB:1UCV}.
FT   HELIX       967    973       {ECO:0000244|PDB:1UCV}.
FT   HELIX       978    995       {ECO:0000244|PDB:1UCV}.
SQ   SEQUENCE   1005 AA;  111003 MW;  6FBF85535E4212B3 CRC64;
     MAPARGRLPP ALWVVTAAAA AATCVSAARG EVNLLDTSTI HGDWGWLTYP AHGWDSINEV
     DESFQPIHTY QVCNVMSPNQ NNWLRTSWVP RDGARRVYAE IKFTLRDCNS MPGVLGTCKE
     TFNLYYLESD RDLGASTQES QFLKIDTIAA DESFTGADLG VRRLKLNTEV RSVGPLSKRG
     FYLAFQDIGA CLAILSLRIY YKKCPAMVRN LAAFSEAVTG ADSSSLVEVR GQCVRHSEER
     DTPKMYCSAE GEWLVPIGKC VCSAGYEERR DACVACELGF YKSAPGDQLC ARCPPHSHSA
     APAAQACHCD LSYYRAALDP PSSACTRPPS APVNLISSVN GTSVTLEWAP PLDPGGRSDI
     TYNAVCRRCP WALSRCEACG SGTRFVPQQT SLVQASLLVA NLLAHMNYSF WIEAVNGVSD
     LSPEPRRAAV VNITTNQAAP SQVVVIRQER AGQTSVSLLW QEPEQPNGII LEYEIKYYEK
     DKEMQSYSTL KAVTTRATVS GLKPGTRYVF QVRARTSAGC GRFSQAMEVE TGKPRPRYDT
     RTIVWICLTL ITGLVVLLLL LICKKRHCGY SKAFQDSDEE KMHYQNGQAP PPVFLPLHHP
     PGKLPEPQFY AEPHTYEEPG RAGRSFTREI EASRIHIEKI IGSGDSGEVC YGRLRVPGQR
     DVPVAIKALK AGYTERQRRD FLSEASIMGQ FDHPNIIRLE GVVTRGRLAM IVTEYMENGS
     LDTFLRTHDG QFTIMQLVGM LRGVGAGMRY LSDLGYVHRD LAARNVLVDS NLVCKVSDFG
     LSRVLEDDPD AAYTTTGGKI PIRWTAPEAI AFRTFSSASD VWSFGVVMWE VLAYGERPYW
     NMTNRDVISS VEEGYRLPAP MGCPHALHQL MLDCWHKDRA QRPRFSQIVS VLDALIRSPE
     SLRATATVSR CPPPAFVRSC FDLRGGSGGG GGLTVGDWLD SIRMGRYRDH FAAGGYSSLG
     MVLRMNAQDV RALGITLMGH QKKILGSIQT MRAQLTSTQG PRRHL
//
